GlycoMimetics receives Nasdaq minimum bid price deficiency notice

CRESCENT BIOPHARMA, INC.

Bid price below $1.00 for 30 consecutive business days; 180-day cure period until Nov 28, 2022.
Compliance requires closing bid price at or above $1.00 for at least 10 consecutive business days.
If not cured, Company may transfer to Nasdaq Capital Market for additional 180-day period if eligible.
Noncompliance has no immediate effect on listing or trading of common stock on The Nasdaq Global Market.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.